Search

Your search keyword '"Antipsychotic Agents administration & dosage"' showing total 9,341 results

Search Constraints

Start Over You searched for: Descriptor "Antipsychotic Agents administration & dosage" Remove constraint Descriptor: "Antipsychotic Agents administration & dosage"
9,341 results on '"Antipsychotic Agents administration & dosage"'

Search Results

1. Advancement in the Nose-to-Brain Drug delivery of FDA-approved drugs for the better management of Depression and Psychiatric disorders.

2. Combining ion-pair strategy and percutaneous permeation enhancers to develop sustained-release paliperidone patch.

3. Medication burden reduction and early clinical benefit through aripiprazole once monthly in schizophrenia patients with polypharmacy.

4. A realist review of medication optimisation of community dwelling service users with serious mental illness.

5. Pharmacokinetic Prediction of Immediate- and Extended-Release Tablets for Patients with Liver Disease Using Whole Body Physiologically-Based Pharmacokinetic Modeling for the Antipsychotic Drug Quetiapine.

6. Lessons learnt in the end-of-life management of a hospice inpatient with advanced oropharyngeal cancer established on clozapine for treatment-resistant schizophrenia.

7. Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study.

8. Paliperidone-loaded nose to brain targeted NLCS: optimisation, evaluation, histopathology and pharmacokinetic estimation for schizophernia.

9. Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis.

10. Clozapine Toxicity Predictor: Deep neural network model predicting clozapine toxicity and its therapeutic dose range.

11. Design and methodology of a randomized clinical trial of quetiapine to reduce central nervous system polypharmacy in veterans with postconcussive syndrome symptoms.

12. Successful treatment with olanzapine and aripiprazole of a schizophrenic patient who developed priapism after switching from risperidone to paliperidone.

13. Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms.

14. Drug-induced parkinsonism: diagnosis and treatment.

15. PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement.

16. Exploring the efficacy and tolerability of two-injection start regimen of long-acting aripiprazole: A descriptive case series analysis.

17. Efficacy of Cariprazine in the Psychosis Spectrum: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials in Schizophrenia and Bipolar Disorder.

18. Unidentified CYP2D6 genotype does not affect pharmacological treatment for patients with first episode psychosis.

19. Towards precision dosing in psychiatry: Population pharmacokinetics meta-modelling of clozapine and lithium.

20. Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users.

21. Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. The SwAP trial II: Results on side effects.

22. Clinical effectiveness of paliperidone palmitate 3-monthly and 1-monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database.

23. Association of antipsychotic formulations with sudden cardiac death in patients with schizophrenia: A nationwide population-based case-control study.

24. Adult and adolescent antipsychotic exposure increases delay discounting and diminishes behavioral flexibility in male C57BL/6 mice.

25. An ethics analysis of antipsychotic dose reduction and discontinuation: Principles for supporting recovery from psychosis.

26. Changing vistas of psychosis and antipsychotic drug dosing toward personalized management of antipsychotics in clinical practice.

27. Assessing the impact of long-acting injectable compared to oral antipsychotic medications on readmission to a state psychiatric hospital.

28. Comparing Intubation Rates in Patients Receiving Parenteral Olanzapine With and Without a Parenteral Benzodiazepine in the Emergency Department.

29. Take It Easy! Serotonin Syndrome Precipitated by the Rapid Titration of Sertraline and Trazodone in the Setting of Risperidone Use.

30. Monitoring momentary subjective well-being and psychotic experiences during antipsychotic dose reduction: Two single-case time series experience sampling method pilot study.

31. Ziprasidone population pharmacokinetics and co-medication effects in Chinese patients.

32. Long-Acting Injectable Antipsychotics in the Geriatric Population: A longitudinal Study.

33. The liminal space of first-episode psychosis and its treatment: A qualitative study exploring the experience of young people participating in an antipsychotic dose reduction randomized controlled trial.

34. Advanced Drug Delivery Technologies for Enhancing Bioavailability and Efficacy of Risperidone.

35. Pharmacotherapy considerations for pediatric acute agitation management in the emergency department.

36. Reduction of benztropine use duration in acute psychiatry: A quality improvement initiative.

37. Olanzapine postinjection delirium/sedation syndrome after long-acting olanzapine depot injection presenting to the emergency department: practical guidelines for diagnosis and management.

38. Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis.

39. Exploring peptide dendrimers for intestinal lymphatic targeting: formulation and evaluation of peptide dendrimer conjugated liposomes for enhancing the oral bioavailability of Asenapine maleate.

40. Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study.

41. Nomogram model for predicting medication adherence in patients with various mental disorders based on the Dryad database.

42. Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study.

43. Making Sense of Recovery From First Psychosis With Antipsychotic Medication: A Qualitative Phenomenological Study.

44. Motivations for and Experiences With Antipsychotic Tapering Among Patients With Schizophrenia Seeking Guided Dose Reduction.

45. Glia dysfunction in schizophrenia: evidence of possible therapeutic effects of nervonic acid in a preclinical model.

46. Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action.

47. Novel long-acting treatment for schizophrenia based on paliperidone dissolving and implantable microarray patches.

48. A Trajectory of Long-Term Antipsychotic Medication Dosage in Inpatients with Severe Behavioral and Psychological Symptoms of Dementia: A Retrospective Study.

49. DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects.

50. Impacts of exposure to and subsequent discontinuation of clozapine on tripartite synaptic transmission.

Catalog

Books, media, physical & digital resources